Global Sexually Transmitted Disease Treatment Market

Sexually Transmitted Disease Treatment Comprehensive Study by Type (Chlamydia, Gonorrhea, Syphilis, Hepatitis B, Genital herpes, HIV/AIDS, Human Papillomavirus, Crabs/Pubic Lice, Others), Application (Prevention of STDs, Diagnosis of STDs), Technology (Phone Chips (Micro-fluidics + ICT), Portable/Bench Top/Rapid Diagnostic Kits, Others), End-User (Hospitals, Diagnostic clinics, Special Hospitals for STDs), Laboratory Devices (Thermal Cyclers - PCR, Lateral Flow Readers, Immuno-chromatographic Assays, Flow Cytometers Absorbance, Micro-plate Reader - Enzyme-Linked Immuno-sorbent Assay (ELISA)), Diagnostic methods (Laboratory testing, Point O care testing), Treatments (Antibiotic, Anti-viral, Vaccines, Others), Age (15-30, 45-54, 65 and older) Players and Region - Global Market Outlook to 2027

Sexually Transmitted Disease Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
STDs stand for Sexually transmitted Diseases also known by sexually transmitted infections. In the past years, it is known as Venereal Disease or VD.STDs is mainly transmitted via Vagina, Anal, and Oral sex mostly. It is also transmitted by trichomoniasis by contact damp or moist such as towels, wet clothing or toilet seats but commonly transmitted by any sexual contact. It is also transmitted through an infected person and infected medical equipment and devices. Another reason for transmission is by a person who has multiple sex partners. Various treatments and diagnostic methods are available some are curable while some disease is just managed not curable.
This growth is primarily driven by Increasing No Of STDs Population and Emerging New Disorders Like Zika Virus.

Globally, a noticeable market trend is evident Growing Use Of Point O Care Treatment. Major Players, such as Abbott Laboratories (United States), MedMira Inc (Canada), Qaigen Inc (Netherlands), Cepheid (Danaher Corporation) (United States), Roche AG Holdings (Switzerland), Diasorin S.p.A (Italy), BioMeriuex (France), Hologic (United States), Bio-Rad Laboratories (United States), Bayer AG (Germany), Merck and Company Inc (United States) and Home Access Health Inc (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 17th December 2019, Roche announced the successful acquisition of Spark therapeutics to enhance the capability in gene therapy. The completion of the acquisition followed the receipt of regulatory approval.
On 5th November 2019, QIAGEN expands its immune-oncology assets for future advancements and development for diagnostic and biomarkers .it has successfully acquired licensing rights for epigenomic (DNA methylation) immune checkpoints from the University of Bonn. It has expanded its plant for commercialization of novel companion diagnostics for precision medicine in oncology.

Regulatory Insights:
On 23rd May 2019, US FDA cleared the first diagnostic tests for extra-genital testing for Chlamydia and gonorrhea. U.S. Food and Drug Administration has recently cleared marketing for its first diagnostic test which will detect the bacteria of Chlamydia trachomatis and Neisseria gonorrhoeae which is the reason for transmitting STDs.

Market Drivers
  • Increasing No Of STDs Population
  • Emerging New Disorders Like Zika Virus

Market Trend
  • Growing Use Of Point O Care Treatment

Restraints
  • Some Disorder Are Highly Incurable And Only Can Be Managed
  • Symptoms And Damages Ignored Due To Social Fear

Opportunities
Growing Awareness About Treatment Of STDs By Various Organisation And Social Platforms
Challenges
Research And Studies Not Getting Results For Enhancement In Treatments and Life-Threatening And High-Cost Associated With Treatment

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Sexually Transmitted Disease Treatment Study Sheds Light on
— The Sexually Transmitted Disease Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Sexually Transmitted Disease Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Sexually Transmitted Disease Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Chlamydia
  • Gonorrhea
  • Syphilis
  • Hepatitis B
  • Genital herpes
  • HIV/AIDS
  • Human Papillomavirus
  • Crabs/Pubic Lice
  • Others
By Application
  • Prevention of STDs
  • Diagnosis of STDs
By Technology
  • Phone Chips (Micro-fluidics + ICT)
  • Portable/Bench Top/Rapid Diagnostic Kits
  • Others

By End-User
  • Hospitals
  • Diagnostic clinics
  • Special Hospitals for STDs

By Laboratory Devices
  • Thermal Cyclers - PCR
  • Lateral Flow Readers
  • Immuno-chromatographic Assays
  • Flow Cytometers Absorbance
  • Micro-plate Reader - Enzyme-Linked Immuno-sorbent Assay (ELISA)

By Diagnostic methods
  • Laboratory testing
  • Point O care testing

By Treatments
  • Antibiotic
  • Anti-viral
  • Vaccines
  • Others

By Age
  • 15-30
  • 45-54
  • 65 and older

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing No Of STDs Population
      • 3.2.2. Emerging New Disorders Like Zika Virus
    • 3.3. Market Challenges
      • 3.3.1. Research And Studies Not Getting Results For Enhancement In Treatments
      • 3.3.2. Life-Threatening And High-Cost Associated With Treatment
    • 3.4. Market Trends
      • 3.4.1. Growing Use Of Point O Care Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sexually Transmitted Disease Treatment, by Type, Application, Technology , End-User, Laboratory Devices , Diagnostic methods, Treatments, Age and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Sexually Transmitted Disease Treatment (Value)
      • 5.2.1. Global Sexually Transmitted Disease Treatment by: Type (Value)
        • 5.2.1.1. Chlamydia
        • 5.2.1.2. Gonorrhea
        • 5.2.1.3. Syphilis
        • 5.2.1.4. Hepatitis B
        • 5.2.1.5. Genital herpes
        • 5.2.1.6. HIV/AIDS
        • 5.2.1.7. Human Papillomavirus
        • 5.2.1.8. Crabs/Pubic Lice
        • 5.2.1.9. Others
      • 5.2.2. Global Sexually Transmitted Disease Treatment by: Application (Value)
        • 5.2.2.1. Prevention of STDs
        • 5.2.2.2. Diagnosis of STDs
      • 5.2.3. Global Sexually Transmitted Disease Treatment by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Diagnostic clinics
        • 5.2.3.3. Special Hospitals for STDs
      • 5.2.4. Global Sexually Transmitted Disease Treatment by: Diagnostic methods (Value)
        • 5.2.4.1. Laboratory testing
        • 5.2.4.2. Point O care testing
      • 5.2.5. Global Sexually Transmitted Disease Treatment by: Treatments (Value)
        • 5.2.5.1. Antibiotic
        • 5.2.5.2. Anti-viral
        • 5.2.5.3. Vaccines
        • 5.2.5.4. Others
      • 5.2.6. Global Sexually Transmitted Disease Treatment by: Age (Value)
        • 5.2.6.1. 15-30
        • 5.2.6.2. 45-54
        • 5.2.6.3. 65 and older
      • 5.2.7. Global Sexually Transmitted Disease Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Sexually Transmitted Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. MedMira Inc (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Qaigen Inc (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cepheid (Danaher Corporation) (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche AG Holdings (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Diasorin S.p.A (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioMeriuex (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hologic (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck and Company Inc (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Home Access Health Inc (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Sexually Transmitted Disease Treatment Sale, by Type, Application, Technology , End-User, Laboratory Devices , Diagnostic methods, Treatments, Age and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Sexually Transmitted Disease Treatment (Value)
      • 7.2.1. Global Sexually Transmitted Disease Treatment by: Type (Value)
        • 7.2.1.1. Chlamydia
        • 7.2.1.2. Gonorrhea
        • 7.2.1.3. Syphilis
        • 7.2.1.4. Hepatitis B
        • 7.2.1.5. Genital herpes
        • 7.2.1.6. HIV/AIDS
        • 7.2.1.7. Human Papillomavirus
        • 7.2.1.8. Crabs/Pubic Lice
        • 7.2.1.9. Others
      • 7.2.2. Global Sexually Transmitted Disease Treatment by: Application (Value)
        • 7.2.2.1. Prevention of STDs
        • 7.2.2.2. Diagnosis of STDs
      • 7.2.3. Global Sexually Transmitted Disease Treatment by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Diagnostic clinics
        • 7.2.3.3. Special Hospitals for STDs
      • 7.2.4. Global Sexually Transmitted Disease Treatment by: Diagnostic methods (Value)
        • 7.2.4.1. Laboratory testing
        • 7.2.4.2. Point O care testing
      • 7.2.5. Global Sexually Transmitted Disease Treatment by: Treatments (Value)
        • 7.2.5.1. Antibiotic
        • 7.2.5.2. Anti-viral
        • 7.2.5.3. Vaccines
        • 7.2.5.4. Others
      • 7.2.6. Global Sexually Transmitted Disease Treatment by: Age (Value)
        • 7.2.6.1. 15-30
        • 7.2.6.2. 45-54
        • 7.2.6.3. 65 and older
      • 7.2.7. Global Sexually Transmitted Disease Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sexually Transmitted Disease Treatment: by Type(USD Million)
  • Table 2. Sexually Transmitted Disease Treatment Chlamydia , by Region USD Million (2016-2021)
  • Table 3. Sexually Transmitted Disease Treatment Gonorrhea , by Region USD Million (2016-2021)
  • Table 4. Sexually Transmitted Disease Treatment Syphilis , by Region USD Million (2016-2021)
  • Table 5. Sexually Transmitted Disease Treatment Hepatitis B , by Region USD Million (2016-2021)
  • Table 6. Sexually Transmitted Disease Treatment Genital herpes , by Region USD Million (2016-2021)
  • Table 7. Sexually Transmitted Disease Treatment HIV/AIDS , by Region USD Million (2016-2021)
  • Table 8. Sexually Transmitted Disease Treatment Human Papillomavirus , by Region USD Million (2016-2021)
  • Table 9. Sexually Transmitted Disease Treatment Crabs/Pubic Lice , by Region USD Million (2016-2021)
  • Table 10. Sexually Transmitted Disease Treatment Others , by Region USD Million (2016-2021)
  • Table 11. Sexually Transmitted Disease Treatment: by Application(USD Million)
  • Table 12. Sexually Transmitted Disease Treatment Prevention of STDs , by Region USD Million (2016-2021)
  • Table 13. Sexually Transmitted Disease Treatment Diagnosis of STDs , by Region USD Million (2016-2021)
  • Table 14. Sexually Transmitted Disease Treatment: by End-User(USD Million)
  • Table 15. Sexually Transmitted Disease Treatment Hospitals , by Region USD Million (2016-2021)
  • Table 16. Sexually Transmitted Disease Treatment Diagnostic clinics , by Region USD Million (2016-2021)
  • Table 17. Sexually Transmitted Disease Treatment Special Hospitals for STDs , by Region USD Million (2016-2021)
  • Table 18. Sexually Transmitted Disease Treatment: by Diagnostic methods(USD Million)
  • Table 19. Sexually Transmitted Disease Treatment Laboratory testing , by Region USD Million (2016-2021)
  • Table 20. Sexually Transmitted Disease Treatment Point O care testing , by Region USD Million (2016-2021)
  • Table 21. Sexually Transmitted Disease Treatment: by Treatments(USD Million)
  • Table 22. Sexually Transmitted Disease Treatment Antibiotic , by Region USD Million (2016-2021)
  • Table 23. Sexually Transmitted Disease Treatment Anti-viral , by Region USD Million (2016-2021)
  • Table 24. Sexually Transmitted Disease Treatment Vaccines , by Region USD Million (2016-2021)
  • Table 25. Sexually Transmitted Disease Treatment Others , by Region USD Million (2016-2021)
  • Table 26. Sexually Transmitted Disease Treatment: by Age(USD Million)
  • Table 27. Sexually Transmitted Disease Treatment 15-30 , by Region USD Million (2016-2021)
  • Table 28. Sexually Transmitted Disease Treatment 45-54 , by Region USD Million (2016-2021)
  • Table 29. Sexually Transmitted Disease Treatment 65 and older , by Region USD Million (2016-2021)
  • Table 30. South America Sexually Transmitted Disease Treatment, by Country USD Million (2016-2021)
  • Table 31. South America Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 32. South America Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 33. South America Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 34. South America Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 35. South America Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 36. South America Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 37. South America Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 38. South America Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 39. Brazil Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 40. Brazil Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 41. Brazil Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 42. Brazil Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 43. Brazil Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 44. Brazil Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 45. Brazil Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 46. Brazil Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 47. Argentina Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 48. Argentina Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 49. Argentina Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 50. Argentina Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 51. Argentina Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 52. Argentina Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 53. Argentina Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 54. Argentina Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 55. Rest of South America Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 56. Rest of South America Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 57. Rest of South America Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 58. Rest of South America Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 59. Rest of South America Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 60. Rest of South America Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 61. Rest of South America Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 62. Rest of South America Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 63. Asia Pacific Sexually Transmitted Disease Treatment, by Country USD Million (2016-2021)
  • Table 64. Asia Pacific Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 65. Asia Pacific Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 66. Asia Pacific Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 67. Asia Pacific Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 68. Asia Pacific Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 69. Asia Pacific Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 70. Asia Pacific Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 71. Asia Pacific Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 72. China Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 73. China Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 74. China Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 75. China Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 76. China Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 77. China Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 78. China Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 79. China Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 80. Japan Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 81. Japan Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 82. Japan Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 83. Japan Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 84. Japan Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 85. Japan Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 86. Japan Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 87. Japan Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 88. India Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 89. India Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 90. India Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 91. India Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 92. India Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 93. India Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 94. India Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 95. India Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 96. South Korea Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 97. South Korea Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 98. South Korea Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 99. South Korea Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 100. South Korea Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 101. South Korea Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 102. South Korea Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 103. South Korea Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 104. Taiwan Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 105. Taiwan Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 106. Taiwan Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 107. Taiwan Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 108. Taiwan Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 109. Taiwan Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 110. Taiwan Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 111. Taiwan Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 112. Australia Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 113. Australia Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 114. Australia Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 115. Australia Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 116. Australia Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 117. Australia Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 118. Australia Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 119. Australia Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 120. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 121. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 122. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 123. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 124. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 125. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 126. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 127. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 128. Europe Sexually Transmitted Disease Treatment, by Country USD Million (2016-2021)
  • Table 129. Europe Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 130. Europe Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 131. Europe Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 132. Europe Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 133. Europe Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 134. Europe Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 135. Europe Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 136. Europe Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 137. Germany Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 138. Germany Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 139. Germany Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 140. Germany Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 141. Germany Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 142. Germany Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 143. Germany Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 144. Germany Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 145. France Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 146. France Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 147. France Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 148. France Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 149. France Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 150. France Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 151. France Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 152. France Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 153. Italy Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 154. Italy Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 155. Italy Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 156. Italy Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 157. Italy Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 158. Italy Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 159. Italy Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 160. Italy Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 161. United Kingdom Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 162. United Kingdom Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 163. United Kingdom Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 164. United Kingdom Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 165. United Kingdom Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 166. United Kingdom Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 167. United Kingdom Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 168. United Kingdom Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 169. Netherlands Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 170. Netherlands Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 171. Netherlands Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 172. Netherlands Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 173. Netherlands Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 174. Netherlands Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 175. Netherlands Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 176. Netherlands Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 177. Rest of Europe Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 178. Rest of Europe Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 179. Rest of Europe Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 180. Rest of Europe Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 181. Rest of Europe Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 182. Rest of Europe Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 183. Rest of Europe Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 184. Rest of Europe Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 185. MEA Sexually Transmitted Disease Treatment, by Country USD Million (2016-2021)
  • Table 186. MEA Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 187. MEA Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 188. MEA Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 189. MEA Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 190. MEA Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 191. MEA Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 192. MEA Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 193. MEA Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 194. Middle East Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 195. Middle East Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 196. Middle East Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 197. Middle East Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 198. Middle East Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 199. Middle East Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 200. Middle East Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 201. Middle East Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 202. Africa Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 203. Africa Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 204. Africa Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 205. Africa Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 206. Africa Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 207. Africa Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 208. Africa Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 209. Africa Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 210. North America Sexually Transmitted Disease Treatment, by Country USD Million (2016-2021)
  • Table 211. North America Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 212. North America Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 213. North America Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 214. North America Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 215. North America Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 216. North America Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 217. North America Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 218. North America Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 219. United States Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 220. United States Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 221. United States Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 222. United States Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 223. United States Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 224. United States Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 225. United States Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 226. United States Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 227. Canada Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 228. Canada Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 229. Canada Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 230. Canada Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 231. Canada Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 232. Canada Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 233. Canada Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 234. Canada Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 235. Mexico Sexually Transmitted Disease Treatment, by Type USD Million (2016-2021)
  • Table 236. Mexico Sexually Transmitted Disease Treatment, by Application USD Million (2016-2021)
  • Table 237. Mexico Sexually Transmitted Disease Treatment, by Technology USD Million (2016-2021)
  • Table 238. Mexico Sexually Transmitted Disease Treatment, by End-User USD Million (2016-2021)
  • Table 239. Mexico Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2016-2021)
  • Table 240. Mexico Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2016-2021)
  • Table 241. Mexico Sexually Transmitted Disease Treatment, by Treatments USD Million (2016-2021)
  • Table 242. Mexico Sexually Transmitted Disease Treatment, by Age USD Million (2016-2021)
  • Table 243. Company Basic Information, Sales Area and Its Competitors
  • Table 244. Company Basic Information, Sales Area and Its Competitors
  • Table 245. Company Basic Information, Sales Area and Its Competitors
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Sexually Transmitted Disease Treatment: by Type(USD Million)
  • Table 256. Sexually Transmitted Disease Treatment Chlamydia , by Region USD Million (2022-2027)
  • Table 257. Sexually Transmitted Disease Treatment Gonorrhea , by Region USD Million (2022-2027)
  • Table 258. Sexually Transmitted Disease Treatment Syphilis , by Region USD Million (2022-2027)
  • Table 259. Sexually Transmitted Disease Treatment Hepatitis B , by Region USD Million (2022-2027)
  • Table 260. Sexually Transmitted Disease Treatment Genital herpes , by Region USD Million (2022-2027)
  • Table 261. Sexually Transmitted Disease Treatment HIV/AIDS , by Region USD Million (2022-2027)
  • Table 262. Sexually Transmitted Disease Treatment Human Papillomavirus , by Region USD Million (2022-2027)
  • Table 263. Sexually Transmitted Disease Treatment Crabs/Pubic Lice , by Region USD Million (2022-2027)
  • Table 264. Sexually Transmitted Disease Treatment Others , by Region USD Million (2022-2027)
  • Table 265. Sexually Transmitted Disease Treatment: by Application(USD Million)
  • Table 266. Sexually Transmitted Disease Treatment Prevention of STDs , by Region USD Million (2022-2027)
  • Table 267. Sexually Transmitted Disease Treatment Diagnosis of STDs , by Region USD Million (2022-2027)
  • Table 268. Sexually Transmitted Disease Treatment: by End-User(USD Million)
  • Table 269. Sexually Transmitted Disease Treatment Hospitals , by Region USD Million (2022-2027)
  • Table 270. Sexually Transmitted Disease Treatment Diagnostic clinics , by Region USD Million (2022-2027)
  • Table 271. Sexually Transmitted Disease Treatment Special Hospitals for STDs , by Region USD Million (2022-2027)
  • Table 272. Sexually Transmitted Disease Treatment: by Diagnostic methods(USD Million)
  • Table 273. Sexually Transmitted Disease Treatment Laboratory testing , by Region USD Million (2022-2027)
  • Table 274. Sexually Transmitted Disease Treatment Point O care testing , by Region USD Million (2022-2027)
  • Table 275. Sexually Transmitted Disease Treatment: by Treatments(USD Million)
  • Table 276. Sexually Transmitted Disease Treatment Antibiotic , by Region USD Million (2022-2027)
  • Table 277. Sexually Transmitted Disease Treatment Anti-viral , by Region USD Million (2022-2027)
  • Table 278. Sexually Transmitted Disease Treatment Vaccines , by Region USD Million (2022-2027)
  • Table 279. Sexually Transmitted Disease Treatment Others , by Region USD Million (2022-2027)
  • Table 280. Sexually Transmitted Disease Treatment: by Age(USD Million)
  • Table 281. Sexually Transmitted Disease Treatment 15-30 , by Region USD Million (2022-2027)
  • Table 282. Sexually Transmitted Disease Treatment 45-54 , by Region USD Million (2022-2027)
  • Table 283. Sexually Transmitted Disease Treatment 65 and older , by Region USD Million (2022-2027)
  • Table 284. South America Sexually Transmitted Disease Treatment, by Country USD Million (2022-2027)
  • Table 285. South America Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 286. South America Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 287. South America Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 288. South America Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 289. South America Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 290. South America Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 291. South America Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 292. South America Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 293. Brazil Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 294. Brazil Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 295. Brazil Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 296. Brazil Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 297. Brazil Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 298. Brazil Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 299. Brazil Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 300. Brazil Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 301. Argentina Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 302. Argentina Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 303. Argentina Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 304. Argentina Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 305. Argentina Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 306. Argentina Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 307. Argentina Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 308. Argentina Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 309. Rest of South America Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 310. Rest of South America Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 311. Rest of South America Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 312. Rest of South America Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 313. Rest of South America Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 314. Rest of South America Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 315. Rest of South America Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 316. Rest of South America Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 317. Asia Pacific Sexually Transmitted Disease Treatment, by Country USD Million (2022-2027)
  • Table 318. Asia Pacific Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 319. Asia Pacific Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 320. Asia Pacific Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 321. Asia Pacific Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 322. Asia Pacific Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 323. Asia Pacific Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 324. Asia Pacific Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 325. Asia Pacific Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 326. China Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 327. China Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 328. China Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 329. China Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 330. China Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 331. China Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 332. China Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 333. China Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 334. Japan Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 335. Japan Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 336. Japan Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 337. Japan Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 338. Japan Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 339. Japan Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 340. Japan Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 341. Japan Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 342. India Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 343. India Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 344. India Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 345. India Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 346. India Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 347. India Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 348. India Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 349. India Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 350. South Korea Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 351. South Korea Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 352. South Korea Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 353. South Korea Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 354. South Korea Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 355. South Korea Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 356. South Korea Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 357. South Korea Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 358. Taiwan Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 359. Taiwan Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 360. Taiwan Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 361. Taiwan Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 362. Taiwan Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 363. Taiwan Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 364. Taiwan Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 365. Taiwan Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 366. Australia Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 367. Australia Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 368. Australia Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 369. Australia Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 370. Australia Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 371. Australia Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 372. Australia Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 373. Australia Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 374. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 375. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 376. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 377. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 378. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 379. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 380. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 381. Rest of Asia-Pacific Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 382. Europe Sexually Transmitted Disease Treatment, by Country USD Million (2022-2027)
  • Table 383. Europe Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 384. Europe Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 385. Europe Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 386. Europe Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 387. Europe Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 388. Europe Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 389. Europe Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 390. Europe Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 391. Germany Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 392. Germany Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 393. Germany Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 394. Germany Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 395. Germany Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 396. Germany Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 397. Germany Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 398. Germany Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 399. France Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 400. France Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 401. France Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 402. France Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 403. France Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 404. France Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 405. France Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 406. France Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 407. Italy Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 408. Italy Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 409. Italy Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 410. Italy Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 411. Italy Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 412. Italy Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 413. Italy Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 414. Italy Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 415. United Kingdom Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 416. United Kingdom Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 417. United Kingdom Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 418. United Kingdom Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 419. United Kingdom Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 420. United Kingdom Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 421. United Kingdom Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 422. United Kingdom Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 423. Netherlands Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 424. Netherlands Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 425. Netherlands Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 426. Netherlands Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 427. Netherlands Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 428. Netherlands Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 429. Netherlands Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 430. Netherlands Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 431. Rest of Europe Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 432. Rest of Europe Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 433. Rest of Europe Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 434. Rest of Europe Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 435. Rest of Europe Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 436. Rest of Europe Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 437. Rest of Europe Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 438. Rest of Europe Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 439. MEA Sexually Transmitted Disease Treatment, by Country USD Million (2022-2027)
  • Table 440. MEA Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 441. MEA Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 442. MEA Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 443. MEA Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 444. MEA Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 445. MEA Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 446. MEA Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 447. MEA Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 448. Middle East Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 449. Middle East Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 450. Middle East Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 451. Middle East Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 452. Middle East Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 453. Middle East Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 454. Middle East Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 455. Middle East Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 456. Africa Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 457. Africa Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 458. Africa Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 459. Africa Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 460. Africa Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 461. Africa Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 462. Africa Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 463. Africa Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 464. North America Sexually Transmitted Disease Treatment, by Country USD Million (2022-2027)
  • Table 465. North America Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 466. North America Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 467. North America Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 468. North America Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 469. North America Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 470. North America Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 471. North America Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 472. North America Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 473. United States Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 474. United States Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 475. United States Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 476. United States Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 477. United States Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 478. United States Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 479. United States Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 480. United States Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 481. Canada Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 482. Canada Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 483. Canada Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 484. Canada Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 485. Canada Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 486. Canada Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 487. Canada Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 488. Canada Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 489. Mexico Sexually Transmitted Disease Treatment, by Type USD Million (2022-2027)
  • Table 490. Mexico Sexually Transmitted Disease Treatment, by Application USD Million (2022-2027)
  • Table 491. Mexico Sexually Transmitted Disease Treatment, by Technology USD Million (2022-2027)
  • Table 492. Mexico Sexually Transmitted Disease Treatment, by End-User USD Million (2022-2027)
  • Table 493. Mexico Sexually Transmitted Disease Treatment, by Laboratory Devices USD Million (2022-2027)
  • Table 494. Mexico Sexually Transmitted Disease Treatment, by Diagnostic methods USD Million (2022-2027)
  • Table 495. Mexico Sexually Transmitted Disease Treatment, by Treatments USD Million (2022-2027)
  • Table 496. Mexico Sexually Transmitted Disease Treatment, by Age USD Million (2022-2027)
  • Table 497. Research Programs/Design for This Report
  • Table 498. Key Data Information from Secondary Sources
  • Table 499. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sexually Transmitted Disease Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Sexually Transmitted Disease Treatment: by Application USD Million (2016-2021)
  • Figure 6. Global Sexually Transmitted Disease Treatment: by End-User USD Million (2016-2021)
  • Figure 7. Global Sexually Transmitted Disease Treatment: by Diagnostic methods USD Million (2016-2021)
  • Figure 8. Global Sexually Transmitted Disease Treatment: by Treatments USD Million (2016-2021)
  • Figure 9. Global Sexually Transmitted Disease Treatment: by Age USD Million (2016-2021)
  • Figure 10. South America Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 11. Asia Pacific Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 12. Europe Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 13. MEA Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 14. North America Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 15. Global Sexually Transmitted Disease Treatment share by Players 2021 (%)
  • Figure 16. Global Sexually Transmitted Disease Treatment share by Players (Top 3) 2021(%)
  • Figure 17. Global Sexually Transmitted Disease Treatment share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 21. MedMira Inc (Canada) Revenue, Net Income and Gross profit
  • Figure 22. MedMira Inc (Canada) Revenue: by Geography 2021
  • Figure 23. Qaigen Inc (Netherlands) Revenue, Net Income and Gross profit
  • Figure 24. Qaigen Inc (Netherlands) Revenue: by Geography 2021
  • Figure 25. Cepheid (Danaher Corporation) (United States) Revenue, Net Income and Gross profit
  • Figure 26. Cepheid (Danaher Corporation) (United States) Revenue: by Geography 2021
  • Figure 27. Roche AG Holdings (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche AG Holdings (Switzerland) Revenue: by Geography 2021
  • Figure 29. Diasorin S.p.A (Italy) Revenue, Net Income and Gross profit
  • Figure 30. Diasorin S.p.A (Italy) Revenue: by Geography 2021
  • Figure 31. BioMeriuex (France) Revenue, Net Income and Gross profit
  • Figure 32. BioMeriuex (France) Revenue: by Geography 2021
  • Figure 33. Hologic (United States) Revenue, Net Income and Gross profit
  • Figure 34. Hologic (United States) Revenue: by Geography 2021
  • Figure 35. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bio-Rad Laboratories (United States) Revenue: by Geography 2021
  • Figure 37. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 39. Merck and Company Inc (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck and Company Inc (United States) Revenue: by Geography 2021
  • Figure 41. Home Access Health Inc (United States) Revenue, Net Income and Gross profit
  • Figure 42. Home Access Health Inc (United States) Revenue: by Geography 2021
  • Figure 43. Global Sexually Transmitted Disease Treatment: by Type USD Million (2022-2027)
  • Figure 44. Global Sexually Transmitted Disease Treatment: by Application USD Million (2022-2027)
  • Figure 45. Global Sexually Transmitted Disease Treatment: by End-User USD Million (2022-2027)
  • Figure 46. Global Sexually Transmitted Disease Treatment: by Diagnostic methods USD Million (2022-2027)
  • Figure 47. Global Sexually Transmitted Disease Treatment: by Treatments USD Million (2022-2027)
  • Figure 48. Global Sexually Transmitted Disease Treatment: by Age USD Million (2022-2027)
  • Figure 49. South America Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 50. Asia Pacific Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 51. Europe Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 52. MEA Sexually Transmitted Disease Treatment Share (%), by Country
  • Figure 53. North America Sexually Transmitted Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • MedMira Inc (Canada)
  • Qaigen Inc (Netherlands)
  • Cepheid (Danaher Corporation) (United States)
  • Roche AG Holdings (Switzerland)
  • Diasorin S.p.A (Italy)
  • BioMeriuex (France)
  • Hologic (United States)
  • Bio-Rad Laboratories (United States)
  • Bayer AG (Germany)
  • Merck and Company Inc (United States)
  • Home Access Health Inc (United States)
Select User Access Type

Key Highlights of Report


Feb 2022 230 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sexually Transmitted Disease Treatment Market Quantitative research analysis
Global Sexually Transmitted Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Sexually Transmitted Disease Treatment market is expected to see a CAGR of % during projected year 2021 to 2027.
Top performing companies in the Global Sexually Transmitted Disease Treatment market are Abbott Laboratories (United States), MedMira Inc (Canada), Qaigen Inc (Netherlands), Cepheid (Danaher Corporation) (United States), Roche AG Holdings (Switzerland), Diasorin S.p.A (Italy), BioMeriuex (France), Hologic (United States), Bio-Rad Laboratories (United States), Bayer AG (Germany), Merck and Company Inc (United States) and Home Access Health Inc (United States), to name a few.
is dominating the Sexually Transmitted Disease Treatment Market.

Know More About Global Sexually Transmitted Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Patient Lifting Equipment Comprehensive Study by Type (Ceiling/Overhead Lift, Stair Lift, Sit to Stand Lift, Bath & Pool Lift), Operations (Electric, Manual, Hydraulic), Installation (Mobile, Fixed)...
$ 3450
Pediatric Home Healthcare Services Comprehensive Study by Type (Skilled Nursing Services, Personal Care Assistance, Rehabilitation Therapy Services), Application (Medical Treatment, Preventive Health...
$ 3500
Targeted Delivery Drugs Comprehensive Study by Application (Hospital, Clinic, Others), Technology (Nanoparticles, Polymers (Micelles, Dendrimers), Monoclonal Antibodies, Gold Nanoparticles-Based Drug...
$ 3750
Cardiac Safety Services Comprehensive Study by Type (Integrated Services, Standalone Services), Application (Clinical Trials, Detection and diagnostic, Medical treatment), Patient Type (Infant and ch...
$ 3750
IVD Antibodies Comprehensive Study by Type (Cardiac Markers, Tumor Markers, Kidney Injury Markers, Infection and Inflammation Antibodies), Application (Immunology, Cancer, Cardiovascular Diseases), E...
$ 3500
Medical Billing Systems Comprehensive Study by Type (Institutional billing, Professional billing, Others), Application (Database management, Financial management, Operational), End Users (Hospitals, ...
$ 3650